6 Matching Annotations
  1. Nov 2024
  2. 52.53.155.43 52.53.155.43
    mcr-24-0490-html.html
    1
    1. scibot 08 Nov 2024
      RRID: CVCL_A770

      DOI: 10.1158/1541-7786.mcr-24-0490

      Resource: (RRID:CVCL_A770)

      Curator: @mzhang007

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/b11ad986f66637a5841b16948270c2781f340162/mcr-24-0490-html.html
  3. May 2024
  4. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Inhibition of NAD+-dependent metabolic processes induces cellular necrosis and tumor regression in rhabdomyosarcoma models
    1
    1. scibot 02 May 2024
      RRID:CVCL_A770

      DOI: 10.1158/1078-0432.CCR-23-0200

      Resource: (RRID:CVCL_A770)

      Curator: @evieth

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10841338/
  5. Jan 2024
  6. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies
    1
    1. scibot 18 Jan 2024
      RRID:CVCL_A770

      DOI: 10.1016/j.isci.2023.108711

      Resource: (RRID:CVCL_A770)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10788224/
  7. Apr 2023
  8. aacrjournals.org aacrjournals.org
    The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models
    1
    1. scibot 21 Apr 2023
      RRID:CVCL_A770

      DOI: 10.1158/1078-0432.CCR-22-1646

      Resource: (RRID:CVCL_A770)

      Curator: @sofiakhan13

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/29/2/472/713978/The-Combination-of-Trametinib-and-Ganitumab-is
  9. Apr 2022
  10. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas
    1
    1. scibot 01 Apr 2022
      CVCL_A770

      DOI: 10.1002/1878-0261.13145

      Resource: (RRID:CVCL_A770)

      Curator: @scibot

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8936514/
  11. Mar 2022
  12. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Selective modulation of a pan-essential protein as a therapeutic strategy in cancer
    1
    1. scibot 04 Mar 2022
      RRID:CVCL_A770

      DOI: 10.1158/2159-8290.CD-20-1213

      Resource: (RRID:CVCL_A770)

      Curator: @evieth

      SciCrunch record: RRID:CVCL_A770

      What is this?
      RRID:CVCL_A770
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8419012/